Technology Overview

Recent studies show that direct intratumoral injection of TLR9 agonists (nucleic acid drugs) can improve the response rate of patients who do not respond to immune checkpoint inhibitors, but current applications are limited to superficial tumors such as melanoma and skin cancer.

To overcome this limitation, ITRI developed an injectable TLR9 agonist using a novel spherical nucleic acid (SNA) delivery technology that enables systemic intravenous administration without surgery. This technology is designed for treating deep metastatic tumors such as metastatic colorectal cancer and breast cancer, enhancing the efficacy of immune checkpoint inhibitor therapies and improving clinical accessibility and convenience.

Technical Superiority

1. Prevents nucleic acid degradation

2. Enhances cellular uptake

3. Enables targeted tissue delivery

4. Achieves complete tumor regression

4. Induces specific immune memory to reduce recurrence

5. Intravenous administration without surgery

Application

1. Treats cancers unresponsive to immune checkpoint inhibitors

2. Applicable to deep-seated tumor therapy

3. High potential in the fast-growing cancer immunotherapy market